Roche's Ventana Medical Systems has just received FDA approval of its Ventana ALK (DF53) as a companion diagnostic for Pfizer's Xalkori to treat non-small cell lung cancer.
Roche's Ventana struck a deal with Halozyme Therapeutics to develop a companion diagnostic test to use with Halozyme's new pancreatic cancer drug, adding to a recent string of collaborations as the company continues to expand its industry footprint.
San Diego's Cypher Genomics has attracted the attention of a biotech legionnaire, teaming up with industry heavyweight Celgene for a companion diagnostics project aimed at uncovering genetic biomarkers that help match patients to a suitable therapy.
Roche's Ventana Medical Systems announced a companion diagnostic agreement centered around Astellas Pharma's cancer fighting ASP5878.
Myriad Genetics is expanding its companion diagnostics partnership with AstraZeneca, planning to use Myriad's BRACAnalysis test to see which metastatic pancreatic cancer patients respond to AstraZeneca's Lynparza (olaparib).
Dako is extending its collaboration with pharma giant Amgen to develop companion diagnostic products for drug development and research. Neither side is revealing financial details, but Dako, now an Agilent company, said the deal will focus on personalized medicine and tests that pair patients with suitable treatments.
HalioDx, a new company focused on cancer companion diagnostics, is kicking off operations after a management buyout at Qiagen's Marseille subsidiary.
Myriad Genetics expanded its partnership with BioMarin Pharmaceutical to use Myriad's myChoice HRD companion diagnostic test to identify which cancer patients are the best fit for BioMarin's talazoparib.
Denmark's Dako is teaming up with Ono Pharmaceutical to develop a test for Ono and Bristol-Myers Squibb's drug for non-small cell lung cancer, Opdivo, adding to its tally of companion diagnostics partnerships and gaining more ground in the field.
Abbott Laboratories' diagnostics unit charted sizable gains in 2014, and the company is continuing its upward momentum in the new year with an exclusive licensing deal with the Institut Curie.